Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178143 | 0.97 | CYP3A4 (0.45) | CYP3A4CYP2C9CYP2C19RORCKCNH2 | |
| SCHEMBL2347420 | 0.93 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19RORCKCNH2 | |
| SCHEMBL2345030 | 0.93 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2C19RORCEPAS1 | |
| SCHEMBL1653573 | 0.92 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19EPAS1 | |
| SCHEMBL1653385 | 0.91 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2C19EPAS1 | |
| SCHEMBL2345051 | 0.91 | CYP3A4 (0.53) | CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL12447867 | 0.90 | CYP3A4 (0.37) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5180307 | 0.90 | CYP3A4 (0.49) | CYP3A4CYP2C9CYP2C19RORCKCNH2 | |
| SCHEMBL5179004 | 0.90 | CYP3A4 (0.43) | CYP3A4CYP2C9CYP2C19RORCKCNH2 | |
| SCHEMBL5179852 | 0.89 | CYP3A4 (0.51) | CYP3A4CYP2C9CYP2C19RORCEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4675959-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| US-7666891-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-02-23 | — | — | US | claimed |
| US-8293778-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-10-23 | — | — | US | disclosed |
| US-20110207688-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DUNN JAMES PATRICK | 2011-08-25 | — | — | US | disclosed |
| US-7666891-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666891-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666891-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2010-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207688-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | MAVS, IRF3, ZC3HAV1 | CYP3A4 114/4885CYP2C9 942/4885CYP2C19 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.